* Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma
* Poster presentation will share final data from Phase 2 basket trial (IOB-022/KN-D38) of IO102-IO103 cancer vaccine plus pembrolizumab for 1L treatment of solid tumors
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announces a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany from October 17-21, 2025.
The oral presentation will highlight the results from the randomized Phase 3 trial assessing the efficacy and safety of IO102-IO103 (IDO/PD-L1 vaccine) in combination with pembrolizumab vs pembrolizumab monotherapy in 1L advanced melanoma. In addition, final data from the Phase 2 basket trial with updated efficacy and safety data, median progression-free survival (PFS), landmark PFS and overall survival data, as well as biomarker and translational data for 1L treatment in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of head and neck (SCCHN), will be presented in a poster session. Details of the presentations are as follows: